Skip to main content
. 2023 Nov 15;12(11):1784–1794. doi: 10.1002/psp4.13064

FIGURE 3.

FIGURE 3

Probability of objective response vs (a) mean serum phosphate concentration change from baseline at C1D8 and C1D15 and (b) pemigatinib AUCss following once‐daily dosing of 13.5 mg pemigatinib. Patients received a single daily dose of 13.5 mg pemigatinib. In (a), black squares represent observed first (0.5–2.1 mg/dL), second (2.1–2.7 mg/dL), third (2.7–3.5 mg/dL), and fourth (3.5–6.3 mg/dL) quartiles of serum phosphate concentration change from baseline. In (b), black squares represent first (817–1828 h·nM), second (1828–2351 h·nM), third (2351–3104 h·nM), and fourth (3104–8446 h·nM) quartiles of pemigatinib AUCss. AUCss, area under the concentration‐time curve at steady‐state; C, cycle; D, day.